Infosys is currently trading at Rs. 3185.00, up by 18.40 points or 0.58 % from its previous closing of Rs. 3166.60 on the BSE.
The scrip opened at Rs. 3186.00 and has touched a high and low of Rs. 3205.00 and Rs. 3132.15 respectively. So far 75096 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3847.20 on 03-Mar-2014 and a 52 week low of Rs. 2343.00 on 20-Jun-2013.
Last one week high and low of the scrip stood at Rs. 3298.00 and Rs. 2978.00 respectively. The current market cap of the company is Rs. 182661.65 crore.
The promoters holding in the company stood at 15.94 % while Institutions and Non-Institutions held 55.76 % and 12.20 % respectively.
Infosys, a global leader in technology, consulting and outsourcing, has launched a cloud-based version of its Clinical Trial Supply Management (CTSM) solution. The new solution helps life sciences companies enhance efficiency of clinical trial processes by driving greater collaboration between pharmaceutical companies and contract research organizations (CROs).
This solution helps to improve the productivity of the overall drug development process. It also helps ensure the timely and accurate supply of drugs to patients at reduced costs. As a result, enterprises can price products competitively while adhering to the stringent standards required to bring products safely to consumers.
The new cloud-based version of the CTSM solution is an enhancement to the existing on-premise version of the CTSM solution – CTSM Add-On Suite 2.2 by Lodestone – that offers a complete set of tools to manage all aspects of complex clinical trials. This covers demand and supply planning as well as distribution across clinical sites. The on-premise version of the solution has been successfully managing clinical trial processes at a number of large global pharmaceutical companies across the US and Europe.